NCT06961383 - Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

March 1, 2028

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Interventions

BIOLOGICAL

NG01 - Autologous bone marrow derived human stromal cells

NG01 is a cellular therapy product of autologous stromal cells derived from the bone marrow of multiple sclerosis (MS) patients. NG01 is provided as a cell suspension for intrathecal injection.

OTHER

Sodium Chloride 0.9%

The placebo for use in the NG01 clinical trial is 0.9% Sodium Chloride Solution for Injection

Trial Locations (2)

33136

University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center - Neurology, Miami

Unknown

Hadassah University Hospital, Jerusalem